Decreased nuclear receptor activity and epigenetic modulation associates with down-regulation of hepatic drug-metabolizing enzymes in chronic kidney disease

FASEB Journal

Volumn 28, Issue 12, 2014, Pages 5388-5397

  Velenosi, Thomas J ^a   Feere, David A ^a   Sohi, Gurjeev ^a   Hardy, Daniel B ^a,b   Urquhart, Bradley L ^a,b  

^a WESTERN UNIVERSITY   (Canada)

^b LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

Chromatin immunoprecipitation; Cytochrome P450; Histone modification; Pharmacokinetics; Uremia

Indexed keywords

CELL NUCLEUS RECEPTOR; CREATININE; CYTOCHROME P450 2C; CYTOCHROME P450 2C11; CYTOCHROME P450 3A; CYTOCHROME P450 3A2; DRUG METABOLIZING ENZYME; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; HISTONE H4; RNA; RNA POLYMERASE II; UREA; CELL RECEPTOR; CYTOCHROME P450; HISTONE; ISOENZYME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BODY WEIGHT; CHROMATIN IMMUNOPRECIPITATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOWN REGULATION; EPIGENETICS; HISTONE ACETYLATION; LIVER MICROSOME; MALE; NEPHRECTOMY; NONHUMAN; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; TESTOSTERONE METABOLISM; UREA BLOOD LEVEL; WESTERN BLOTTING; ACETYLATION; ANIMAL; CHRONIC KIDNEY FAILURE; ENZYMOLOGY; GENETIC EPIGENESIS; GENETICS; METABOLISM; SPRAGUE DAWLEY RAT;

RATTUS;

ACETYLATION; ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DOWN-REGULATION; EPIGENESIS, GENETIC; HISTONES; ISOENZYMES; KIDNEY FAILURE, CHRONIC; MICROSOMES, LIVER; PROMOTER REGIONS, GENETIC; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84919779596     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.14-258780     Document Type: Article

References (46)

1. Talbert, R. L. (1994) Drug dosing in renal insufficiency. J. Clin. Pharmacol. 34, 99-110
2. Manley, H. J., Cannella, C. A., Bailie, G. R., and St. Peter, W. L. (2005) Medication-related problems in ambulatory hemodialysis patients: a pooled analysis. Am. J. Kidney Dis. 46, 669-680
3. Leblond, F. A., Giroux, L., Villeneuve, J. P., and Pichette, V. (2000) Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab. Dispos. 28, 1317-1320
4. Nolin, T. D., Frye, R. F., Le, P., Sadr, H., Naud, J., Leblond, F. A., Pichette, V., and Himmelfarb, J. (2009) ESRD impairs nonrenal clearance of fexofenadine but not midazolam. J. Am. Soc. Nephrol. 20, 2269-2276
5. Sun, H., Frassetto, L. A., Huang, Y., and Benet, L. Z. (2010) Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease. Clin. Pharmacol. Ther. 87, 465-472
6. Zanger, U. M., and Schwab, M. (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 138, 103-141
7. Leblond, F., Guevin, C., Demers, C., Pellerin, I., Gascon-Barre, M., and Pichette, V. (2001) Downregulation of hepatic cytochrome P450 in chronic renal failure. J. Am. Soc. Nephrol. 12, 326-332
8. Leblond, F. A., Petrucci, M., Dube, P., Bernier, G., Bonnardeaux, A., and Pichette, V. (2002) Downregulation of intestinal cytochrome p450 in chronic renal failure. J. Am. Soc. Nephrol. 13, 1579-1585
9. Michaud, J., Dube, P., Naud, J., Leblond, F. A., Desbiens, K., Bonnardeaux, A., and Pichette, V. (2005) Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br. J. Pharmacol. 144, 1067-1077
10. Michaud, J., Nolin, T. D., Naud, J., Dani, M., Lafrance, J. P., Leblond, F. A., Himmelfarb, J., and Pichette, V. (2008) Effect of hemodialysis on hepatic cytochrome P450 functional expression. J. Pharmacol. Sci. 108, 157-163
11. Velenosi, T. J., Fu, A. Y., Luo, S., Wang, H., and Urquhart, B. L. (2012) Down-regulation of hepatic CYP3A and CYP2C mediated metabolism in rats with moderate chronic kidney disease. Drug Metab. Dispos. 40, 1508-1514
12. Tirona, R. G., Lee, W., Leake, B. F., Lan, L. B., Cline, C. B., Lamba, V., Parviz, F., Duncan, S. A., Inoue, Y., Gonzalez, F. J., Schuetz, E. G., and Kim, R. B. (2003) The orphan nuclear receptor HNF4α determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat. Med. 9, 220-224
13. Urquhart, B. L., Tirona, R. G., and Kim, R. B. (2007) Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J. Clin. Pharmacol. 47, 566-578
14. Ibeanu, G. C., and Goldstein, J. A. (1995) Transcriptional regulation of human CYP2C genes: functional comparison of CYP2C9 and CYP2C18 promoter regions. Biochemistry 34, 8028-8036
15. Ahmed, J. H., Grant, A. C., Rodger, R. S., Murray, G. R., and Elliott, H. L. (1991) Inhibitory effect of uraemia on the hepatic clearance and metabolism of nicardipine. Br. J. Clin. Pharmacol. 32, 57-62
16. Naud, J., Nolin, T. D., Leblond, F. A., and Pichette, V. (2012) Current understanding of drug disposition in kidney disease. J. Clin. Pharmacol. 52, 10S-22S
17. Nolin, T. D., Naud, J., Leblond, F. A., and Pichette, V. (2008) Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin. Pharmacol. Ther. 83, 898-903
18. Sun, H., Huang, Y., Frassetto, L., and Benet, L. Z. (2004) Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab. Dispos. 32, 1239-1246
19. Velenosi, T. J., and Urquhart, B. L. (2014) Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis. Expert Opin. Drug Metab. Toxicol. 10, 1131-1143
20. Duranton, F., Cohen, G., De Smet, R., Rodriguez, M., Jankowski, J., Vanholder, R., and Argiles, A. (2012) Normal and pathologic concentrations of uremic toxins. J. Am. Soc. Nephrol. 23, 1258-1270
21. Noh, H., Oh, E. Y., Seo, J. Y., Yu, M. R., Kim, Y. O., Ha, H., and Lee, H. B. (2009) Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-β1-induced renal injury. Am. J. Physiol. Renal Physiol. 297, F729-F739
22. Sun, G., Reddy, M. A., Yuan, H., Lanting, L., Kato, M., and Natarajan, R. (2010) Epigenetic histone methylation modulates fibrotic gene expression. J. Am. Soc. Nephrol. 21, 2069-2080
23. Dwivedi, R. S., Herman, J. G., McCaffrey, T. A., and Raj, D. S. (2011) Beyond genetics: epigenetic code in chronic kidney disease. Kidney Int. 79, 23-32
24. Barrero, M. J., and Malik, S. (2006) Two functional modes of a nuclear receptor-recruited arginine methyltransferase in transcriptional activation. Mol. Cell 24, 233-243
25. Cui, J. Y., Gunewardena, S. S., Rockwell, C. E., and Klaassen, C. D. (2010) ChIPing the cistrome of PXR in mouse liver. Nucleic Acids Res. 38, 7943-7963
26. Xie, Y., Ke, S., Ouyang, N., He, J., Xie, W., Bedford, M. T., and Tian, Y. (2009) Epigenetic regulation of transcriptional activity of pregnane X receptor by protein arginine methyltransferase 1. J. Biol. Chem. 284, 9199-9205
27. Sohi, G., Marchand, K., Revesz, A., Arany, E., and Hardy, D. B. (2011) Maternal protein restriction elevates cholesterol in adult rat offspring due to repressive changes in histone modifications at the cholesterol 7α-hydroxylase promoter. Mol. Endocrinol. 25, 785-798
28. Huss, J. M., Wang, S. I., and Kasper, C. B. (1999) Differential glucocorticoid responses of CYP3A23 and CYP3A2 are mediated by selective binding of orphan nuclear receptors. Arch. Biochem. Biophys. 372, 321-332
29. Jenuwein, T., and Allis, C. D. (2001) Translating the histone code. Science 293, 1074-1080
30. Shilatifard, A. (2006) Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. Annu. Rev. Biochem. 75, 243-269
31. Okabe, H., Hasunuma, M., and Hashimoto, Y. (2003) The hepatic and intestinal metabolic activities of P450 in rats with surgery- and drug-induced renal dysfunction. Pharm. Res. 20, 1591-1594
32. Souidi, M., Gueguen, Y., Linard, C., Dudoignon, N., Grison, S., Baudelin, C., Marquette, C., Gourmelon, P., Aigueperse, J., and Dublineau, I. (2005) In vivo effects of chronic contamination with depleted uranium on CYP3A and associated nuclear receptors PXR and CAR in the rat. Toxicology 214, 113-122
33. Ni, S., Wang, X., Wang, J., Zeng, S., and Zhao, Z. (2009) Expression of CYP3A23/1, CYP3A2, PXR, CAR and HNF4α in large-for-gestational-age neonatal rats. Pharmazie 64, 252-257
34. Xu, D. X., Wang, J. P., Sun, M. F., Chen, Y. H., and Wei, W. (2006) Lipopolysaccharide downregulates the expressions of intestinal pregnane X receptor and cytochrome P450 3a11. Eur. J. Pharmacol. 536, 162-170
35. Tian, Y. (2013) Epigenetic regulation of pregnane X receptor activity. Drug Metab. Rev. 45, 166-172
36. Gu, X., Ke, S., Liu, D., Sheng, T., Thomas, P. E., Rabson, A. B., Gallo, M. A., Xie, W., and Tian, Y. (2006) Role of NF-κB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. J. Biol. Chem. 281, 17882-17889
37. Park, S. H., and Waxman, D. J. (2001) Inhibitory cross-talk between STAT5b and liver nuclear factor HNF3β: impact on the regulation of growth hormone pulse-stimulated, male-specific liver cytochrome P-450 gene expression. J. Biol. Chem. 276, 43031-43039
38. Wauthier, V., and Waxman, D. J. (2008) Sex-specific early growth hormone response genes in rat liver. Mol. Endocrinol. 22, 1962-1974
39. Tian, Y. (2009) Ah receptor and NF-κB interplay on the stage of epigenome. Biochem. Pharmacol. 77, 670-680
40. Wu, Y., Shi, X., Liu, Y., Zhang, X., Wang, J., Luo, X., and Wen, A. (2012) Histone deacetylase 1 is required for carbamazepine-induced CYP3A4 expression. J. Pharm. Biomed. Anal. 58, 78-82
41. Lorincz, M. C., Dickerson, D. R., Schmitt, M., and Groudine, M. (2004) Intragenic DNA methylation alters chromatin structure and elongation efficiency in mammalian cells. Nat. Struct. Mol. Biol. 11, 1068-1075
42. Lempiainen, H., Muller, A., Brasa, S., Teo, S. S., Roloff, T. C., Morawiec, L., Zamurovic, N., Vicart, A., Funhoff, E., Couttet, P., Schubeler, D., Grenet, O., Marlowe, J., Moggs, J., and Terranova, R. (2011) Phenobarbital mediates an epigenetic switch at the constitutive androstane receptor (CAR) target gene Cyp2b10 in the liver of B6C3F1 mice. PLoS One 6, e18216
43. Takai, D., and Jones, P. A. (2002) Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc. Natl. Acad. Sci. U. S. A. 99, 3740-3745
44. De, M. S., Orlando, R., Bertoli, M., Pegoraro, P., and Palatini, P. (2006) Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis. Clin. Pharmacol. Ther. 80, 597-606
45. Michaud, J., Naud, J., Chouinard, J., Desy, F., Leblond, F. A., Desbiens, K., Bonnardeaux, A., and Pichette, V. (2006) Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure. J. Am. Soc. Nephrol. 17, 3041-3048
46. Luoma, P. V. (2008) Cytochrome P450 and gene activation- from pharmacology to cholesterol elimination and regression of atherosclerosis. Eur. J. Clin. Pharmacol. 64, 841-850